Can-Fite BioPharma Ltd. (CANF) Form 6-K — Nov 18, 2026
Can-Fite BioPharma announced that all 247 patients in the interim-analysis cohort of its pivotal Phase III psoriasis study have completed dosing of oral Piclidenoson. The pre-specified interim analysis, conducted by an Independent Data Monitoring Committee under a protocol agreed with both the FDA and EMA, is expected to read out in Q1 2027, evaluating PASI 75 and sPGA 0/1 co-primary endpoints at Week 16.
Key figures
- Interim readout
- Q1 2027
- Piclidenoson dose
- 3 mg twice daily
- Co primary endpoints
- ["PASI 75 at Week 16","sPGA 0/1 at Week 16"]
- Interim cohort patients
- 247
- Safety database subjects
- more than 1,500
- Patients in clinical studies
- over 1,700
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.